11月1日，贝康医疗-B(02170)盘中上涨5.71%，截至15:37，报3.33元/股，成交114.97万元。
苏州贝康医疗股份有限公司主要从事生物科技在生育健康领域的产品研发和临床应用，特别是针对不孕不育家庭的解决方案，其研发的PGT-A试剂盒填补了我国在三代试管婴儿中胚胎检测试剂盒的临床空白。2021年，公司在香港联合交易所成功上市，成为辅助生殖领域第一家上市的IVD公司，2022年，总面积7万多平方米的贝康医疗总部基地顺利封顶，未来将围绕生育健康领域构建试剂、耗材、仪器的先进制造基地。
截至2024年中报，贝康医疗-B营业总收入1.25亿元、净利润-1.2亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.